Evidence map›Paper›PMID 31767348›Full record

ArticleBiosensors & bioelectronics2020

3D printed microfluidic devices for circulating tumor cells (CTCs) isolation.

Juhong Chen, Chun-Yen Liu, Xinchang Wang, Eric Sweet, Nathaniel Liu, Xiaohua Gong, Liwei Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosensors & bioelectronics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Bioprinted research models of urological malignancy.Exploration (Beijing, China) · 2024
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Recent Advances in Methods for Circulating Tumor Cell Detection.International journal of molecular sciences · 2023
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Juhong ChenDepartment of Mechanical Engineering, University of California, Berkeley, USA; Berkeley Sensor and Actuators Center, USA; Department of Biological Systems Engineering, Virginia Tech, USA; Hangzhou Institute of Advanced Transducing Technology, Wahaha R&D Academe, Hangzhou, China. Electronic address: jhchen@vt.edu.
Chun-Yen LiuSchool of Optometry and Vision Science Program, University of California, Berkeley, USA; Department of Materials Science and Engineering, National Cheng Kung University, Tainan, Taiwan.
Xinchang WangDepartment of Mechanical Engineering, University of California, Berkeley, USA; School of Mechanical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Eric SweetDepartment of Mechanical Engineering, University of California, Berkeley, USA; Berkeley Sensor and Actuators Center, USA.
Nathaniel LiuDepartment of Mechanical Engineering, University of California, Berkeley, USA.
Xiaohua GongSchool of Optometry and Vision Science Program, University of California, Berkeley, USA.
Liwei LinDepartment of Mechanical Engineering, University of California, Berkeley, USA; Berkeley Sensor and Actuators Center, USA. Electronic address: lwlin@berkeley.edu.

Funding

Cataracts, Connexin Mutants and Genetic ModifiersR01EY013849 · NEI · UNIVERSITY OF CALIFORNIA BERKELEY · PI Xiaohua Gong · 2002 to 2026
$8.2M
NEI NIH HHS R01 EY013849
6 · The paper itself

Abstract

Isolation of circulating tumor cells (CTCs) from blood samples has important prognostic and therapeutic implications for cancer treatments, but the process is very challenging due to the low concentration of CTCs. In this study, we report a novel 3D printed microfluidic device functionalized with anti-EpCAM (epithelial cell adhesion molecule) antibodies to isolate CTCs from human blood samples. A 3D printing technology was utilized with specially designed interior structures to fabricate a microfluidic device with high surface area and fluid flow manipulation, increasing capture efficiency of tumor cells. These devices with the optimal flow rate (1 mL/h) and channel length (2 cm) were demonstrated to test three kinds of EpCAM positive cancer cell lines (MCF-7 breast cancer, SW480 colon cancer, and PC3 prostate cancer), and one kind of EpCAM negative cancer cell line (293T kidney cancer). Experimentally, the capture efficiency higher than 90% has been achieved, and the isolation of MCF-7 tumor cells from spiked human blood samples has also been demonstrated. Combined with DNA-based detection (e.g. polymerase chain reaction or DNA sequencing), the detection and analysis of released DNAs from captured tumor cells could be another future direction for clinical diagnosis and cancer treatment.

Indexed as

Lab-On-A-Chip DevicesAntibodies, ImmobilizedBiosensing TechniquesCell SeparationEquipment DesignHumansNeoplasmsNeoplastic Cells, CirculatingPrinting, Three-DimensionalAntibodies, Immobilized3D printingCirculating tumor cell (CTC)DiagnosticsImmunocaptureMicrofluidic separation

Identifiers

PMID31767348
PMCPMC9266647

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.